News | Radiation Therapy | October 19, 2016

IBA and Philips Launch Patient-centric Ambient Experience Solution for Proton Therapy

Ambient Experience uses modern technology and design to create a more comfortable and soothing experience for patients and staff during proton therapy

IBA, Philips, Ambient Experience, proton therapy, Proteus One, Proteus Plus, ASTRO 2016

October 19, 2016 — IBA (Ion Beam Applications SA) and Philips announced in September the launch of a dedicated patient-centric Ambient Experience solution for the proton therapy gantry of IBA’s Proteus Plus proton therapy solution. The announcement makes the Philips solution now available for both Proteus One and Proteus Plus.

Designed and engineered by Philips, Ambient Experience is an interactive, patient-focused healthcare environment that uses modern technology and people-centric design to create a more comfortable and soothing experience for patients and staff, helping to improve workflows and increase operational effectiveness. Implemented in IBA’s proton therapy gantries, patients are able to select their preferred theme, light, sound and video prior to undergoing treatment. By enhancing the clinical environment, Philips’ Ambient Experience improves patient comfort and staff experience and satisfaction. In 2014, Philips received an international Red Dot Award for product design for its dedicated Proteus One Ambient Experience solution.

The new Ambient Experience development is part of a broader collaboration between the two companies that also includes the joint marketing and sales of IBA’s proton therapy solutions and Philips’ imaging and clinical informatics solutions.

"The Philips Ambient Experience is one of the many differentiators of the Proteus One solution,” said Lane Rosen, M.D., at Willis-Knighton Cancer Center in Shreveport, La., the first IBA center to use Philips Ambient Experience. “Patients have the ability to change their color themes, music and video. Our patients enjoy the experience as it helps them to relax during treatment and remain still. The Ambient Experience atmosphere is calming for the staff as well as the therapist for this most meticulous of treatments."

"Cancer treatment can be a frightening experience, so making the environment as pleasant as possible is essential to reduce stress,” said Prof. Karol Sikora, chief medical officer of U.K.-based Proton Partners International, which is currently building three proton therapy centers. “We believe lighting, design and music will help to create a relaxing and soothing experience. And it will make our staff more relaxed too, by creating an atmosphere of greater empathy. We look forward to operating our first center with Philips Ambient Experience next year in Newport, Wales."
 
In 2016, IBA and Philips plan to equip four additional rooms in the United States: three Proteus Plus rooms in the Miami Cancer Institute, and one Proteus One at the Beaumont Hospital in Royal Oak, Mich. In addition, Philips and IBA have a pipeline of rooms to be equipped with Philips Ambient Experience features in the U.K., Middle East, U.S. and Taiwan.

For more information: www.iba-worldwide.com, www.usa.philips.com/healthcare

Related Content

Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...